BRAF and melanoma: Secondary resistance to BRAF inhibitors in melanoma (Table 4) can be classified into two forms: adaptive resistance (Figure 4), which arises early through reversible cellular reprogramming, and acquired resistance (Figure 5), which develops later through stable genetic or epigenetic alterations.